Yu #AGBTph18 $850B in revenue, 9% of plans participate in 'value-based reimb programs'. Scoring by vendors, CMS bonus or penalties
12:33pm September 8th 2018 via Twitter Web Client
Yu #AGBTph18 Outline: healthcare landscape, clinical genomic appl, and oppy's. Precis Med: predisposition, pharmaco… https://t.co/8ZS5pIz9oI
12:31pm September 8th 2018 via Twitter Web Client
Ben Yu (Interpreta) #AGBTph18 Genomics and AI in clinical medicine
12:27pm September 8th 2018 via Twitter Web Client
Q: How does Takeda look at working w/academia? Plump #AGBTph18 Vast majority of what they do is partner; 180 signed in 3y
12:24pm September 8th 2018 via Twitter Web Client
Plump #AGBTph18 ID'd genes to modulate for this particular nucleus of the brain. bacTRAP (bact. artificial chr. tra… https://t.co/rGiVYNckiI
12:20pm September 8th 2018 via Twitter Web Client
Plump #AGBTph18 Optogenetic ablation of dorsal medial habenula (in animals get behavioral deficit, here a wheel-run… https://t.co/tjsd8EGoTS
12:19pm September 8th 2018 via Twitter Web Client
Plump #AGBTph18 Have preclin data, and Takeda is testing this candidate for narcolepsy Rx. nAChrR (Nicotinic achety… https://t.co/wMKUybHq3N
12:16pm September 8th 2018 via Twitter Web Client
Plump #AGBTph18 Story in humans: an HLA predisposition, some env event (incl infection w/virus). Loss of orexin-pro… https://t.co/nlztWAd2qz
12:15pm September 8th 2018 via Twitter Web Client
Plump #AGBTph18 1999 Stanford group positionally-cloned the gene for narcolepsy from this breed of dog. Orexin-producing neurons
12:14pm September 8th 2018 via Twitter Web Client
Plump #AGBTph18 Shows a 15-year old WKNO PBS video on narcoleptic dogs. Youtube: https://t.co/CRqlnLmA21
12:13pm September 8th 2018 via Twitter Web Client
Plump #AGBTph18 And then test novel Takeda molecules; 84% cell lines respond positively. Different pts iPSCs vs nov… https://t.co/Xd3THz36Mh
12:11pm September 8th 2018 via Twitter Web Client
Plump #AGBTph18 They use iPSCs to dev cell-based Rx; also to dev small-molecule Rx. Treating ALS- motor neurons fro… https://t.co/jNo9zNDktF
12:09pm September 8th 2018 via Twitter Web Client
Plump #AGBTph18 Not just genetic observation; it's functional models. CiRA https://t.co/Ky78NRYbPC with Yamanaka's… https://t.co/cLnAbfCmsW
12:08pm September 8th 2018 via Twitter Web Client
Plump #AGBTph18 Rare disease is linear: replacing enzyme activity etc. Pipeline slide: 5/18, 2/16; 12/23: 'targets… https://t.co/zUUxalhq7c
12:07pm September 8th 2018 via Twitter Web Client
Plump #AGBTph18 Takeda's focus is Oncology, GI, Neuro and Vaccines. First 3 is all genetics; Shire acquisition underway (rare disease)
12:06pm September 8th 2018 via Twitter Web Client
Plump #AGBTph18 '15 Nature Gen https://t.co/lNB8cRlEH0 For later settings, #'s with genetic assoc's increase
12:05pm September 8th 2018 via Twitter Web Client
Plump #AGBTph18 How is a target chosen? More and more, 'humans are the way to choose targets'. Human validation: ge… https://t.co/TVXQ6gkt0E
12:04pm September 8th 2018 via Twitter Web Client
Plump #AGBTph18 Making a new drug 'is almost magic'; the cost is astronomical; an energizing endeavor but takes over decade.
12:03pm September 8th 2018 via Twitter Web Client
Andrew Plump (Takeda) #AGBTph18 Leveraging human genetics to deliver new therapies to patients
12:02pm September 8th 2018 via Twitter Web Client
McKenzie #AGBTph18 They have built an info-sharing collaborating tool. McLeod: They've setup a system for review.
9:34pm September 7th 2018 via Twitter Web Client
Cross-institutional tumor boards? #AGBTph18 McKenzie They consider themselves the scientific advisors; they present digestable info.
9:32pm September 7th 2018 via Twitter Web Client
If cost were not a question, what to do? #AGBTph18 McKenzie Co's with organoid Rx, not ridiculous to consider. Bala… https://t.co/5hmCDT1guI
9:29pm September 7th 2018 via Twitter Web Client
Rehm #AGBTph18 Adding trios instead of individuals for germline and ID de novo variants, saved so much in solving cases at hi rate
9:27pm September 7th 2018 via Twitter Web Client
Berger #AGBTph18 They do have a targeted RNA panel, if nothing was found or SV at DNA level where RNA needed to resolve.
9:26pm September 7th 2018 via Twitter Web Client
Mardis: What about RNA-Seq usage for fusions? #AGBTph18 McLeod Gene fusions are druggable, they recently switched t… https://t.co/cH7Peth8RQ
9:25pm September 7th 2018 via Twitter Web Client
McLeod #AGBTph18 A 'radiology scan model', where you look at it, and a radiologist also looks at it.
9:23pm September 7th 2018 via Twitter Web Client
McKenzie #AGBTph18 Imptc to review all what is known about the case, as many stories of pts w/VUS who resp to Rx
9:22pm September 7th 2018 via Twitter Web Client
McKenzie #AGBTph18 Commercial tests are ordered; he wished that VUS's were tiered, as they are just in a long list on the last page.
9:21pm September 7th 2018 via Twitter Web Client
Rehm #AGBTph18 In germline, 67% of the vars in their reports 'you never would see again'. 7 tiers instead of 5: exp… https://t.co/XAMgEczGMx
9:16pm September 7th 2018 via Twitter Web Client
McLeod #AGBTph18 What to do with VAKS ('variants of almost known significance')? Is one case enough to guide Rx?
9:15pm September 7th 2018 via Twitter Web Client
Berger #AGBTph18 Germline has been done at MSK from the beginning 5y ago. Only recently returning results.
9:14pm September 7th 2018 via Twitter Web Client
Berger #AGBTph18 Is TSC mut a LoF mut, leading to possible mTOR Rx? Rehm: Why are not normal controls required, for… https://t.co/g3ikC6SpAi
9:10pm September 7th 2018 via Twitter Web Client
McKenzie #AGBTph18 PTEN LOF mut another target. 'Our resp is to present physicians with these options'
9:07pm September 7th 2018 via Twitter Web Client
McKenzie #AGBTph18 Colon ca progressed: look thru clin trial menu to look for match. KRAS, there are new ras-direct… https://t.co/hIU5oFQ6SN
9:06pm September 7th 2018 via Twitter Web Client
McLeod #AGBTph18 Results - KRAS, ERBB32, PTEN, long list incl APC, SMAD, EPHA7, AXIN muts. MSI stable, TMB low 6 mut/Mbase.
9:05pm September 7th 2018 via Twitter Web Client
Rehm #AGBTph18 But how will we learn? May add genes but only interpret the relevant ones, and add'l data is IRB-app… https://t.co/TYbZo6e9aa
9:04pm September 7th 2018 via Twitter Web Client
McLeod A broad panel gives free research; who pays? #AGBTph18 Rehm: Germline testing carryover: an arms race. ClinG… https://t.co/XQmIX75hzR
9:02pm September 7th 2018 via Twitter Web Client
RT @HolliHDilks: Great to see Dr Andrew McKenzie of @SarahCannonDocs participating in the Mock Tumor Board at #agbtph18 #FightingCancerToge…
9:01pm September 7th 2018 via Twitter Web Client
McKenzie #AGBTph18 Also what is easy to order for them, given the vol of pts they see. One test provider - wanted l… https://t.co/xTGX122V2w
McLeod #AGBTph18 Rep brings a new test w/3 genes 'better', then what? McKenzie We look for utility. Drs. are very pragmatic: Rx relevance
9:00pm September 7th 2018 via Twitter Web Client
McLeod #AGBTph18 What somatic panel to use? Berger: Common sig is MSI. Colon ca is tested for MSI commonly via IHC.
8:59pm September 7th 2018 via Twitter Web Client
McLeod #AGBTph18 FOLFIRI + beva Rx 7mos. Mixed response, prog in one liver lesion. After 1st and 2nd standard lines… https://t.co/9ubSB3WCVT
8:57pm September 7th 2018 via Twitter Web Client
McLeod #AGBTph18 Case 2: 54yo fem, StgIII colon carcinoma, 5+ lymph, KRAS+, sigmoid resection, FOLFOX 6 mos. Rx. 9m… https://t.co/pOzm1g8RNs
8:56pm September 7th 2018 via Twitter Web Client
Rehm #AGBTph18 Incredibly useful, critical to bring knowledge together. The importance of data-sharing - and its value.
8:55pm September 7th 2018 via Twitter Web Client
McLeod:KRAS - what to care about? #AGBTph18 Rehm: Inst. building their own db's, replicating lots of work. CiVIC wo… https://t.co/pyNotvCE9Y
8:54pm September 7th 2018 via Twitter Web Client
Berger #AGBTph18 Is there a gold std for TMB? One test to recalibrate everything - 'we're still grappling'
8:52pm September 7th 2018 via Twitter Web Client
Berger #AGBTph18 IMPACT vs WES: higher numbers for IMPACT, due to selection of highly mutated genes. Different labs… https://t.co/kdy2we1hTE
Berger #AGBTph18 Depriving pt b/c of low TMB, how good is TMB as a biomarker? 16 mut/Mbase dep on type of cancer. TMB is assay-dependent.
8:51pm September 7th 2018 via Twitter Web Client
McLeod: Heterogeneity? Berger #AGBTph18 TMB is a focus now: due to ImmunoRx response. We 'struggle with that' as low TMB may still respond.
8:50pm September 7th 2018 via Twitter Web Client
McKenzie #AGBTph18 Could be a good cand for I-O studies. MYC: pharma is looking for MYC ampl for clin trial Rx
8:49pm September 7th 2018 via Twitter Web Client
